4'-Fluoro-2'-Methyl Nucleoside Derivatives for HCV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C Virus (HCV) infection are limited, with only two approved therapies available, and there is a lack of effective cell-based viral replication assays or animal models for evaluating nucleoside inhibitors.
Innovation Solution
Development of specific purine and pyrimidine nucleoside derivatives, such as those of Formula I, which inhibit subgenomic HCV RNA replication in hepatoma cell lines, potentially serving as antiviral drugs for HCV treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current approved therapies (interferon-α monotherapy or combination with ribavirin) are used, then treatment options are limited, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent introduces novel nucleoside derivative compounds with modified chemical structures (Formula I variants) to improve therapeutic efficacy. These compounds represent parameter changes in molecular structure designed to enhance antiviral activity against HCV while maintaining selectivity, directly addressing the insufficiency of current therapies
2Measurement precision
If nucleoside analogues are evaluated using cell-based assays, then direct evaluation of HCV replication inhibition is possible, but lack of true cell-based viral replication assay or animal model limits evaluation accuracy
Solution Approach 1:
The patent utilizes subgenomic HCV replicon cell lines as an intermediary system that allows evaluation of nucleoside analogue inhibitors without requiring complete viral replication cycles. This intermediary model provides sufficient measurement precision for drug evaluation while avoiding the complexity of full animal models or infectious viral systems
3Ease of operation
If only two approved therapies are available, then treatment simplicity is maintained, but therapeutic effectiveness is compromised
Solution Approach 1:
The patent segments the therapeutic approach by introducing multiple new nucleoside derivative compounds with different structural variants (Formula I with various R groups) that can be evaluated and potentially combined. This segmentation allows for systematic improvement of therapeutic effectiveness while maintaining manageable treatment protocols
Data Source
AI summary
The present disclosure relates to 4'-fluoro-2'-methyl substitured nucleoside derivatives, pharmaceutical compositions thereof, and methods of using such compounds and/or compositions thereof, for the treatment of HCV.